TheJakartaPost

Please Update your browser

Your browser is out of date, and may not be compatible with our website. A list of the most popular web browsers can be found below.
Just click on the icons to get to the download page.

Jakarta Post

S.Korea's Celltrion to begin commercial production of COVID-19 antibody drug

  • Sangmi Cha

    Reuters

Seoul, South Korea   /   Tue, September 8, 2020   /   05:30 pm
S.Korea's Celltrion to begin commercial production of COVID-19 antibody drug The logo of Celltrion is seen at the company's headquarters in Incheon, South Korea, Oct, 28, 2016.South Korea expects clinical trials of Celltrion Inc's experimental COVID-19 treatment to begin in Europe next month and aims to secure sizable supplies of the drug by the first half of next year, a senior health official said on Tuesday. (Reuters/Kim Hong-Ji)

South Korea's Celltrion Inc will begin commercial production of its experimental treatment for COVID-19 this month, it said on Tuesday, as it pushes ahead with clinical trials of the antibody drug.

The company said it planned to make a request soon to regulators for emergency use authorization of the drug, but that it would start mass production - likely to amount to around 1 million doses - before receiving that approval.

The treatment became the country's first COVID-19 antibody drug to be tested on humans after receiving regulatory approval in July for clinical trials.

"We have confirmed the safety of the antiviral antibody drug in the process of the local Phase I clinical trial," Kwon Ki-sung, head of Celltrion's R&D unit, told Reuters.

Celltrion completed a Phase I trial on 32 volunteers in the country and is enrolling an additional nine participants for another Phase I study before moving on to later stage trials, for which regulatory reviews are already underway.

The company is separately conducting overseas human trials of its treatment in the United Kingdom, which will be followed by global second and third stage trials in patients with mild and moderate symptoms.

Shares of Celltrion surged as much as 5.6% on Tuesday, while the broader KOSPI gained 0.7%.

Other companies developing potential COVID-19 treatments include Eli Lilly and Co, Regeneron Pharmaceuticals Inc and AbbVie.